Company Filing History:
Years Active: 2007
Title: Maria Athanasiou: Innovator in Genetic Markers and Alzheimer's Treatment
Introduction
Maria Athanasiou is a prominent inventor based in Derby, Connecticut. She has made significant contributions to the field of genetics, particularly in relation to Alzheimer's treatment. Her innovative work focuses on the CDK5 genetic markers and their association with cognitive responses to galantamine.
Latest Patents
Maria holds a patent for her groundbreaking work titled "CDK5 genetic markers associated with galantamine response." This patent discloses haplotypes in the CDK5 gene that are linked to cognitive responses to galantamine treatment. The patent outlines compositions and methods for detecting and utilizing these CDK5 haplotypes in various clinical applications. These applications include articles of manufacture comprising galantamine or its derivatives, which are approved for treating patients with specific CDK5 haplotypes. Additionally, the patent describes methods and kits for predicting an individual's response to galantamine based on their haplotype profile, as well as treatment methods for Alzheimer's patients tailored to their haplotype profiles.
Career Highlights
Maria is currently associated with Pgxhealth, LLC, where she continues to advance her research and innovations. Her work has the potential to significantly impact the treatment of Alzheimer's disease, providing new avenues for personalized medicine.
Collaborations
Some of her notable coworkers include Jeroen Aerssens and Carlos Brain, who contribute to her research efforts and collaborative projects.
Conclusion
Maria Athanasiou is a trailblazer in the field of genetics, with her patent on CDK5 genetic markers paving the way for advancements in Alzheimer's treatment. Her contributions are vital to the ongoing research and development of personalized medical solutions.